Amended Current Report Filing (8-k/a)
May 27 2022 - 4:30PM
Edgar (US Regulatory)
0000350737
true
OCEAN BIO CHEM INC
0000350737
2022-05-27
2022-05-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
May 27, 2022
OCEAN BIO-CHEM, INC.
(Exact name of registrant as specified in charter)
Florida |
|
0-11102 |
|
59-1564329 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification No.) |
4041 S.W. 47 Avenue, Fort Lauderdale, Florida |
|
33314 |
(Address of principal executive offices) |
|
(Zip Code) |
(954) 587-6280
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which
registered |
|
|
|
|
|
Common Stock, $0.01 par value |
OBCI |
The NASDAQ Stock Market |
Item 8.01 Other Events.
Explanatory Note:
The Company is filing
this Amendment No. 1 on Form 8-K to report that on May 26, 2022, the Company reported the declaration of the Company’s quarterly
dividend. The record date and payment date of the divided has been added to the 8-K filing as follows:
On May 25,
2022, Ocean Bio-Chem, Inc. (the “Company”) the Board of Directors voted and approved the quarterly regular dividend of $0.04
per/share.
Record date
the quarterly dividend is June 8, 2022, and payment date is June 23, 2022.
The information furnished pursuant to Item 8.01 of this Current Report,
including the exhibits furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into future
filings by the Company under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless
the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by
reference therein.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
OCEAN BIO-CHEM, INC. |
|
|
|
Date: May 27, 2022 |
By: |
/s/ Jeffrey S. Barocas |
|
|
Jeffrey S. Barocas |
|
|
Chief Financial Officer |
2
Ocean Bio Chem (NASDAQ:OBCI)
Historical Stock Chart
From Apr 2024 to May 2024
Ocean Bio Chem (NASDAQ:OBCI)
Historical Stock Chart
From May 2023 to May 2024